(Q33558693)

28 July 2017

title

Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis (English)

1 reference

28 July 2017

0 references

1 reference

Mao Mao An

1

1 reference

28 July 2017

Zui Zou

2

1 reference

28 July 2017

Hui Shen

3

1 reference

28 July 2017

Ping Liu

4

1 reference

28 July 2017

Meng Li Chen

5

1 reference

28 July 2017

Yong Bing Cao

6

1 reference

28 July 2017

Yuan Ying Jiang

7

1 reference

28 July 2017

publication date

17 April 2010

1 reference

European Journal of Clinical Pharmacology

28 July 2017

published in

1 reference

28 July 2017

volume

66

1 reference

28 July 2017

issue

8

1 reference

28 July 2017

page(s)

813-821

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-010-0815-4

28 July 2017

exact match

0 references

cites work

Tumor angiogenesis: therapeutic implications

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-010-0815-4

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-010-0815-4

Why sources of heterogeneity in meta-analysis should be investigated

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-010-0815-4

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

12 December 2020

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

1 reference

12 December 2020

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

12 December 2020

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

12 December 2020

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

1 reference

12 December 2020

Meta-analysis in clinical trials

1 reference

12 December 2020

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

12 December 2020

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

12 December 2020

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

12 December 2020

Assessing the quality of randomized controlled trials. Current issues and future directions

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

12 December 2020

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

12 December 2020

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

1 reference

12 December 2020

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

12 December 2020

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

12 December 2020

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

12 December 2020

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

12 December 2020

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

12 December 2020

The importance of quality of primary studies in producing unbiased systematic reviews

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

Summing up evidence: one answer is not always enough.

1 reference

12 December 2020

10.1007/S00228-010-0815-4

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1015076191

0 references

Fatcat ID

release_527fkaukrjcvnmbd5hhzasce2q

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/527fkaukrjcvnmbd5hhzasce2q

24 November 2022

mapped directly with Wikidata item

1 reference